Tsiang M, Lentz S R, Sadler J E
Howard Hughes Medical Institute, Jewish Hospital of Saint Louis, Washington University School of Medicine, Missouri 63110.
J Biol Chem. 1992 Mar 25;267(9):6164-70.
Thrombomodulin is an endothelial cell thrombin receptor that serves as a cofactor for thrombin-catalyzed activation of protein C. Structural requirements for thrombin binding and cofactor activity were studied by mutagenesis of recombinant human thrombomodulin expressed on COS-7 and CV-1 cells. Deletion of the fourth epidermal growth factor (EGF)-like domain abolished cofactor activity but did not affect thrombin binding. Deletion of either the fifth or the sixth EGF-like domain markedly reduced both thrombin binding affinity and cofactor activity. Thrombin binding sequences were also localized by assaying the ability of synthetic peptides derived from thrombomodulin to compete with diisopropyl fluorophosphate-inactivated 125I-thrombin binding to thrombomodulin. The two most active peptides corresponded to (a) the entire third loop of the fifth EGF-like domain (Kp = 85 +/- 6 microM) and (b) parts of the second and third loops of the sixth EGF-like domain (Kp = 117 +/- 9 microM). These data suggest that thrombin interacts with two discrete elements in thrombomodulin. Deletion of the Ser/Thr-rich domain dramatically decreased both thrombin binding affinity and cofactor activity and also prevented the formation of a high molecular weight thrombomodulin species containing chondroitin sulfate. Substitutions of this domain with polypeptide segments of decreasing length and devoid of glycosylation sites progressively decreased both cofactor activity and thrombin binding affinity. This correlation suggests that increased proximity of the membrane surface to the thrombin binding site may hinder efficient thrombin binding and the subsequent activation of protein C. Membrane-bound thrombomodulin therefore requires the Ser/Thr-rich domain as an important spacer, in addition to EGF-like domains 4-6, for efficient protein C activation.
血栓调节蛋白是一种内皮细胞凝血酶受体,作为凝血酶催化蛋白C活化的辅因子。通过对在COS-7和CV-1细胞上表达的重组人血栓调节蛋白进行诱变,研究了凝血酶结合和辅因子活性的结构要求。删除第四个表皮生长因子(EGF)样结构域可消除辅因子活性,但不影响凝血酶结合。删除第五个或第六个EGF样结构域均显著降低凝血酶结合亲和力和辅因子活性。还通过测定源自血栓调节蛋白的合成肽与二异丙基氟磷酸酯灭活的125I-凝血酶结合血栓调节蛋白的竞争能力,定位了凝血酶结合序列。两个活性最高的肽对应于:(a)第五个EGF样结构域的整个第三环(Kp = 85±6μM)和(b)第六个EGF样结构域的第二和第三环的部分(Kp = 117±9μM)。这些数据表明,凝血酶与血栓调节蛋白中的两个离散元件相互作用。删除富含丝氨酸/苏氨酸的结构域显著降低凝血酶结合亲和力和辅因子活性,也阻止了含有硫酸软骨素的高分子量血栓调节蛋白物种的形成。用长度逐渐减小且无糖基化位点的多肽片段替换该结构域,会逐渐降低辅因子活性和凝血酶结合亲和力。这种相关性表明,膜表面与凝血酶结合位点的距离增加可能会阻碍有效的凝血酶结合和随后的蛋白C活化。因此,膜结合的血栓调节蛋白除了4-6个EGF样结构域外,还需要富含丝氨酸/苏氨酸的结构域作为重要的间隔物,以实现有效的蛋白C活化。